Skip to content

AOCI at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$24.8M-63.6%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$569K-387%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$115K-10.6%
Zymeworks logo
ZymeworksZYME
-$6.57M-2.5%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$56K-75.2%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
-$883K

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's AOCI?
MAZE (MAZE) reported AOCI of -$135K in Q1 2026.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.